Funded by venture capital and based in China, IMPACT Therapeutics, Inc. (IMPACT) is dedicated to the discovery, development and commercialization of novel and “best-in-class” therapeutics to treat cancer and other life-threatening diseases. IMPACT is a clinical-stage company with a unique small-molecule drug discovery and development platform targeting DDR. IMPACT’s leading program, PARP inhibitor IMP4297, is currently undergoing Phase I trials in Australia and China.
IMPACT has a highly experienced management team. Dr. Ye Edward Tian, the CEO and CSO, came from Transtech Pharma in High Point, NC with 20 years of drug discovery experience. Served as Research Fellow and Associate Director, Dr. Tian played critical roles in several drug discovery projects that have advanced to clinical trials. Prior to that, he was a Senior Scientist at Pfizer in Ann Arbor, MI. Dr. Tian received his PhD in Neuroscience and Pharmacology from Michigan State University. Dr. Sui Xiong Cai, the SVP and CTO, joined the company from San Diego, CA with more than 20 years of drug discovery experience. Served as Senior Director of Chemistry at EpiCept, Maxim Pharmaceuticals and Cytovia Inc., Dr. Cai has played critical roles in several anticancer projects that have resulted in two drugs in Phase II clinical trials, andtrials. He is an inventor of more than 80 90 US issued US patents and he received his PhD in Organic Chemistry from University of Oregon.
IMPACT has discovered two series of novel PARP inhibitors, and selected IMP4297 as a clinical candidate for clinicaldrug development. IMP4297 is currently in Phase I studies in Australia and in China. ExcellentGood safety profile, high oral absorption, and good preliminary efficacy data have been obtained from the ongoing dose escalation studies. IMPACT has discovered three series of novel Hedgehog inhibitors, and selected IMP5471 as a clinical candidate for development. The company has also discovered IMP3138, a small molecular microtubule inhibitor clinical candidate, which has advantages both in vitro and in vivo over paclitaxel. IMPACT is committed to develop morealso has discovered several series of inhibitors targeting DNA damage response pathway.
IMPACT closed Series A financing led by Lilly Asia Ventures, Cenova Capital and Wuxi AppTec Ventures in July 2014, and Series B financing led by China Summit Capital, Guangzhou YUEXIU Industrial Investment Fund, Sungent Bioventure, HAIBANG Ventures and Lilly Asia Ventures in December 2015.